



Policy code	DTP_INF_0125	
Date	January, 2025	
Purpose	To ensure a consistent procedural approach to influenze vaccine 2023 administration.	
Scope	Applies to all Queensland Ambulance Service (QAS) clinical staff.	
Health care setting	Pre-hospital assessment and treatment.	
Population	Applies to all ages unless specifically mentioned.	
Source of funding	Internal – 100%	
Author	Clinical Quality & Patient Safety Unit, QAS	
Review date	January, 2027	
Information security	UNCLASSIFIED – Queensland Government Information Security Classification Framework.	
URL	https://ambulance.qld.gov.au/clinical.html	

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by appropriately qualified QAS clinicians when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Ambulance Service) 2024.



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.o/deed.en

 $For copyright permissions beyond the scope of this license please contact: \underline{Clinical.Guidelines@ambulance.qld.gov.au}\\$

Influenza vaccine 2025

January, 2025

Drug class

Vaccine^[1]

Pharmacology

Inactivated split virus vaccine for the prevention of southern hemisphere influenza virus types A and B.[1]

Metabolism

Not applicable.

Indications

Note: Influenza vaccines may only be administered by paramedics with specific approval of the QAS Medical Director.

• Prevention of seasonal influenza for QAS employees

Contraindications

- Allergy AND/OR Adverse Drug Reaction to an influenza vaccine and/or components
- Known allergy to eggs or egg products

Refer to General Practitioner for any of the following:

- Current immune-oncologic therapy
- Hypersensitivity to the influenza vaccine
 AND/OR its components (as listed on the
 Consumer Medicines Information)
- Current episode of febrile illness (temperature greater than 38.5°C) or acute systemic illness
- Bleeding disorders OR current anti-coagulant therapy
- History of Guillain-Barre syndrome

UNCONTROLLED WHEN PRINTED

Precautions

- Persons who are:
 - aged 65 years or over OR
 - pregnant OR
 - breastfeeding OR
 - immunocompromised

It is recommended these persons speak to their GP first. Those aged 65 years or over are recommended to receive a different influenza vaccine to assist with a stronger immune response.

N	

Side effects

- Allergic reaction
- Discomfort, redness and swelling at the injection site
- Headache
- Malaise
- Mild fever

Presentation

 Injection (pre-filled syringe) Afluria[®] Quad, FLUAD[®] Quad, FluQuadri™, Vaxigrop Tetra™ and Fluarix[®] Tetra.

Onset	Duration	Half-life
Variable	Variable	N/A

Schedule

S4 (Restricted drugs).

Routes of administration

Intramuscular injection (IM)



Special notes

- Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the QAS Clinical Consultation and Advice Line.
- The influenza vaccine has been shown to be very effective at preventing influenza.
- Only ambulance officers who are authorised by the QAS Medical Director and have undergone the required education and training are permitted to possess and/or administer the influenza vaccination.

Special notes

- Paramedic immunisers must:
 - read this Drug Therapy Protocol (DTP) in conjunction with the Paramedic Immuniser Document and CPP: *QAS employee* influenza vaccination.
 - only administer the influenza vaccination, with consent, to a QAS employee. Paramedic immunisers must not administer the influenza vaccination to the general public.
 - have access to the current online edition of the Australian Immunisation Handbook when providing an influenza immunisation clinic.
 - ensure vaccine cold chain management is maintained in accordance with the *Strive for Five National Vaccine Storage Guidelines*.
 - ensure that adrenaline is immediately available in case of anaphylaxis or severe allergic reaction.
 - be aware of 'Shoulder Injury Related to Vaccine Administration (SIRVA)' complication that is caused by administering the vaccine too high in the shoulder joint.
- To report an adverse reaction to influenza vaccination, submit the Adverse Event Following Immunisation (AEFI) Form published on the Queensland Health website.
- Vaccine recipients must be observed by the paramedic immuniser
 for 15 minutes and must not operate a vehicle during this time.

Adult dosages [1]

For the prevention of seasonal influenza for QAS employees



IM

Afluria[®] Quad, FluQaudri[™], INFLUVAC TETRA, Fluarix[®] Tetra OR Vaxigrip Tetra[™]

Inject pre-filled syringe slowly over a count of 5 seconds into the deltoid. **Single dose only.**

IDDINITED

WHEN PRINTED